|
Medcaw Investments Ltd on Thursday noted a narrowed pretax loss in 2025, and maintained a positive view on potential growth through acquistion activity. The London-based investment firm targets precious metal mining projects. Back in December, it agreed on binding heads of terms to buy a controlling share of the Eagle Lake gold project in Ontario, Canada, via reverse takeover. Also in December, the company outlined plans to transfer its listing to London’s AIM, away from the main market. As a result, Medcaw shares currently are suspended from trading. The stock is down 27% from 4.0 pence in April 2025. The company’s pretax loss narrowed to £144,478 in 2025 from £432,360 in 2024. Loss per share narrowed to 0.65p from 1.95p and Medcaw booked no revenue, unchanged on-year. Its cash balance was £320,829 at the end of December, up from £72,286 a year prior. Non-Executive Chair Marcus Yeoman acknowledged that it had been ‘a challenging period,’ but remained optimistic about the firm’s prospects. ‘2025 saw Medcaw take decisive steps to reposition the company for growth,’ Yeoman said. ‘The board believes that the proposed acquisition of the Eagle Lake Gold Project in Ontario, if completed, could represent a significant strategic pivot and provide shareholders with exposure to a quality gold asset in a Tier 1 mining jurisdiction. The proposed move to AIM would provide a more suitable platform to deliver long-term value, with access to a broader natural resources investor base. The board is pleased with the progress being made and looks forward to updating shareholders further in due course.’ Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
